BUSINESS WIRE -- Transcatheter heart valve company CardiAQ Valve Technologies (“CVT”), which is developing the world’s first self-conforming and self-anchoring technology for Transcatheter Mitral Valve Implantation (TMVI), announced today that its Phase 1 porcine model study has clearly demonstrated the capability of its proprietary transcatheter delivery system to successfully and repeatedly deliver a mitral valve implant. Arshad Quadri, M.D., Co-Founder, Chairman and Chief Medical Officer of CVT, will be presenting the results of this significant research on Wed., Sept. 22, at the Transcatheter Cardiovascular Therapeutics (“TCT”) scientific meeting in Washington, D.C. (3:30 p.m. ET, Room 147AB, Washington Convention Center).
